The diagnosis of primary leiomyosarcoma (LMS) of bone is generally established based on integrative findings of morphologic features, immunohistochemical staining, and clinical and radiological findings. There are no specific genetic alterations that can be used to confirm the diagnosis of LMS in challenging diagnoses of bone sarcomas with myogenic differentiation. In this study, we assessed the utility of a DNA methylation-based classifier as an ancillary diagnostic tool for subclassifying bone sarcomas with myogenic differentiation. DNA methylation profiling using the Deutsches Krebsforschungszentrum classifier system was performed on 5 patients with available formalin-fixed paraffin-embedded tissue blocks. The original diagnosis of LMS was retained in 2 of 5 patients. Three patients were reclassified as having malignant giant cell tumor of the bone, malignant peripheral nerve sheath tumor, or undifferentiated pleomorphic sarcoma/myxofibrosarcoma after integrating the results of the DNA methylation-based classifier with the clinicopathologic, immunohistochemical, and radiologic findings. While a DNA methylation-based classifier can serve as a useful ancillary tool for refining the subclassification of primary bone sarcomas with myogenic differentiation, especially for diagnostically challenging tumors, integrating clinical, histopathological, and radiological findings is essential for obtaining a final diagnosis.
AntonescuCRErlandsonRAHuvosAG. Primary leiomyosarcoma of bone: a clinicopathologic, immunohistochemical, and ultrastructural study of 33 patients and a literature review. Am J Surg Pathol. 1997;21(11):1281-1294.
2.
WangGYLucasDR. Primary leiomyosarcoma of bone: review and update. Arch Pathol Lab Med. 2019;143(11):1332-1337.
3.
GushoCABlankATGitelisS. Comparison of clinicopathological features and outcomes in patients with primary leiomyosarcoma of bone and soft tissue. J Surg Oncol. 2021;123(5):1274-1283.
4.
Chudasama P, Mughal SS, Sanders MA, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018;9(1):144.
5.
Koelsche C, Schrimpf D, Stichel D, et al. Sarcoma classification by DNA methylation profiling. Nat Commun. 2021;12(1):498.
6.
Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469-474.
7.
Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun. 2015;6:7557. doi:https://doi.org/10.1038/ncomms8557
8.
de Almeida BC, Dos Anjos LG, Dobroff AS, et al. Epigenetic features in uterine leiomyosarcoma and endometrial stromal sarcomas: An overview of the literature. Biomedicines. 2022;10(10). doi:https://doi.org/10.3390/biomedicines10102567.
9.
Kommoss FKF, Stichel D, Schrimpf D, et al. DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. J Cancer Res Clin Oncol. 2020;146(1):97-104.
10.
Miettinen M, Abdullaev Z, Turakulov R, et al. Assessment of the utility of the sarcoma DNA methylation classifier in surgical pathology. Am J Surg Pathol. 2024;48(1):112-122.
11.
CoindreJM. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med. 2006;130(10):1448-1453.
12.
Adams EJ, Green JA, Clark AH, Youngson JH. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol. 1999;52(1):75-77.
13.
Capper D, Stichel D, Sahm F, et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. Acta Neuropathol. 2018;136(2):181-210.
14.
Bady P, Sciuscio D, Diserens AC, et al. MGMT methylation analysis of glioblastoma on the infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124(4):547-560.
15.
Sbaraglia M, Righi A, Gambarotti M, Vanel D, Picci P, Dei Tos AP. Soft tissue tumors rarely presenting primary in bone; diagnostic pitfalls. Surg Pathol Clin. 2017;10(3):705-730.
16.
Romeo S, Bovee JV, Kroon HM, et al.. Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch. 2012;461(5):561-570.
17.
Hemingway F, Kashima TG, Mahendra G, et al. Smooth muscle actin expression in primary bone tumours. Virchows Arch. 2012;460(5):525-534.
18.
Perez-Montiel MD, Plaza JA, Dominguez-Malagon H, Suster S. Differential expression of smooth muscle myosin, smooth muscle actin, h-caldesmon, and calponin in the diagnosis of myofibroblastic and smooth muscle lesions of skin and soft tissue. Am J Dermatopathol. 2006;28(2):105-111.
19.
Altmannsberger M, Weber K, Droste R, Osborn M.Desmin is a specific marker for rhabdomyosarcomas of human and rat origin. Am J Pathol. 1985;118(1):85-95.
20.
HornickJLFletcherCD. Sclerosing PEComa: clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum. Am J Surg Pathol. 2008;32(4):493-501.
21.
Folpe AL, Fanburg-Smith JC, Miettinen M, Weiss SW. Atypical and malignant glomus tumors: analysis of 52 cases, with a proposal for the reclassification of glomus tumors. Am J Surg Pathol. 2001;25(1):1-12.
22.
MatsuyamaAHisaokaMHashimotoH. Angioleiomyoma: a clinicopathologic and immunohistochemical reappraisal with special reference to the correlation with myopericytoma. Hum Pathol. 2007;38(4):645-651.
23.
Choi J, Manzano A, Dong W, et al. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci USA. 2021;118(15). doi:https://doi.org/10.1073/pnas.2025182118
24.
Davila A, Conrad EU, Ayala GE, Beckmann NM. Intraosseous malignant peripheral nerve sheath tumor of the sacrum in a patient with neurofibromatosis type I. Radiol Case Rep. 2019;14(7):880-884.
25.
Gambarotti M, Righi A, Sbaraglia M, et al. Primary malignant peripheral nerve sheath tumors of bone: a clinicopathologic reappraisal of 8 cases. Hum Pathol. 2022;122:92-102.
26.
Muthusamy S, Conway SA, Pitcher JD, Temple HT. Primary intraosseous malignant peripheral nerve sheath tumor of the medial cuneiform: a case report and review of the literature. J Foot Ankle Surg. 2017;56(1):129-134.
27.
SchaeferIMFletcherCDHornickJL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29(1):4-13.
28.
MochH.Soft Tissue and Bone Tumours WHO Classification of Tumours/Volume 3. WHO Classification of Tumours, 2020; 3.
29.
Thangaiah JJ, Westling BE, Roden AC, et al. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Ann Diagn Pathol. 2022;59:151967. doi:https://doi.org/10.1016/j.anndiagpath.2022.151967
30.
Cortes-Ciriano I, Steele CD, Piculell K, et al. Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. Cancer Discov. 2023;13(3):654-671.
31.
Behjati S, Tarpey PS, Presneau N, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479-1482.
32.
Presneau N, Baumhoer D, Behjati S, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1(2):113-123.
33.
Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in giant cell tumor of bone: a review of the literature. Technol Cancer Res Treat. 2019;18:1533033819840000. doi:https://doi.org/10.1177/1533033819840000
34.
BertoniFBacchiniPStaalsEL. Malignancy in giant cell tumor of bone. Cancer. 2003;97(10):2520-2529.
35.
Tsukamoto Y, Futani H, Kihara T, et al. An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation. Pathol Res Pract. 2018;214(9):1504-1509.
36.
Righi A, Mancini I, Gambarotti M, et al. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol. 2017;68:128-135. doi: https://doi.org/10.1016/j.humpath.2017.08.033
37.
KoelscheC, et al.Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. Clin Sarcoma Res. 2017;7:9. doi:https://doi.org/10.1186/s13569-017-0075-5
38.
Tvrdik T, Gjeorgjievski SG, Wong P, Oskouei S, Read W, Bahrami A. Genomic insights into high-grade infarct-associated bone sarcomas. Mod Pathol. 2024;37(10):100572.
39.
FrassicaFJSimFHWoldLE. Case report 462: grade 2 myxoid fibrosarcoma of femur. Skeletal Radiol. 1988;17(1):77-80.
40.
KapurPSarodeV. Pathologic quiz case: myxoid tibial lesion in a 31-year-old man. Low-grade myxofibrosarcoma. Arch Pathol Lab Med. 2004;128(4):e65-e66.
41.
Zhang Q, Wojno TH, Yaffe BM, Grossniklaus HE. Myxofibrosarcoma of the orbit: a clinicopathologic case report. Ophthalmic Plast Reconstr Surg. 2010;26(2):129-131.
42.
KayserD, Walton Z, Bruner E, Chapin RW. Myxofibrosarcoma: first report of myxofibrosarcoma of bone arising at a bone infarct. Skeletal Radiol. 2017;46(8):1143-1147.
43.
SunH, Liu J, Hu F, et al.Current research and management of undifferentiated pleomorphic sarcoma/myofibrosarcoma. Front Genet. 2023;14:1109491. doi:https://doi.org/10.3389/fgene.2023.1109491
44.
LyskjaerI, De Noon S, Tirabosco R, et al.DNA methylation-based profiling of bone and soft tissue tumours: a validation study of the ‘DKFZ sarcoma classifier’. J Pathol Clin Res. 2021;7(4):350-360.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
